Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2007

01-08-2007 | Original Paper

Unlicensed and off-label use of medicines at a neonatology clinic in Italy

Authors: Maria Dell’Aera, Anna Rita Gasbarro, Margherita Padovano, Nicola Laforgia, Donatella Capodiferro, Biagio Solarino, Roberto Quaranta, Alessandro S. Dell’Erba

Published in: International Journal of Clinical Pharmacy | Issue 4/2007

Login to get access

Abstract

Objective

Many drugs used for children are not licensed or are used off-label. An increased risk of medication errors and unexpected adverse drug reactions (ADR) associated with off-label and unlicensed drug prescription has been reported. This risk increases in the newborn, who are more likely to be predisposed to an ADR due to their physiological immaturity. The objective of this study was to describe the use of unlicensed or off-label drugs in a Neonatal Intensive Care Unit (NICU).

Methods

All drugs prescribed to newborn admitted to the Neonatology Unit of Bari University Hospital, from July 1st to August 31st in 2004 were recorded.

Main outcome measures

All the drugs prescribed were analysed with regard to their license status, then the licensed drugs were compared to the indications, dose, route of administration, duration of treatment, contraindications and warnings specified in the summary of product characteristics of the marketing authorization.

Results

Data were collected on 176 prescriptions for 61 different drugs given to 34 newborns. Drugs were licensed in 88% and unlicensed in 12% of cases. About the licensed drugs, in 37.5% medicines were used following the terms of the marketing authorization, in 22.7% of cases medicines were used in an off-label manner as they contained no information for paediatric use in the marketing authorization and in 27.8% of cases medicines were licensed for paediatric use, but they were used off-label with regard to age, dose, route of administration and duration of treatment.

Conclusions

Despite European and American initiatives aiming to promote greater awareness and research in the paediatric population, these data demonstrate that there is still a high percentage of unlicensed or off-label drugs use in neonatology, underlining the need to stimulate scientific data collection by means of experimental studies or outcome research.
Literature
1.
2.
go back to reference Kauffman RE. Status of drug approval processes and regulation of medications for children. Curr Opin Pediatr 1995;7:195–8.PubMedCrossRef Kauffman RE. Status of drug approval processes and regulation of medications for children. Curr Opin Pediatr 1995;7:195–8.PubMedCrossRef
4.
go back to reference Avenel S, Bomkratz A, Dasssieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product licence in a neonatal intensive care unit. Arch Pediatr 2000;7:143–7.PubMedCrossRef Avenel S, Bomkratz A, Dasssieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product licence in a neonatal intensive care unit. Arch Pediatr 2000;7:143–7.PubMedCrossRef
5.
go back to reference O’Donnell CP, Stone RS, Morley CJ. Unlicensed and Off-label drug use in an australian neonatal intensive care unit. Pediatrics 2002;110(5):e52.PubMedCrossRef O’Donnell CP, Stone RS, Morley CJ. Unlicensed and Off-label drug use in an australian neonatal intensive care unit. Pediatrics 2002;110(5):e52.PubMedCrossRef
6.
go back to reference ‘t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics 2001;108:1089–93.PubMedCrossRef ‘t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics 2001;108:1089–93.PubMedCrossRef
7.
go back to reference ‘t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. Unapproved and off-label use of drugs in a children’s hospital. New Engl J Med 2000;343:1125.PubMedCrossRef ‘t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. Unapproved and off-label use of drugs in a children’s hospital. New Engl J Med 2000;343:1125.PubMedCrossRef
8.
go back to reference Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off-label drug use in European countries. BMJ 2000;320(7227):79–82.PubMedCrossRef Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off-label drug use in European countries. BMJ 2000;320(7227):79–82.PubMedCrossRef
9.
go back to reference McIntyre J, Conroy S, Avery A, Corus H, Choonara I. Unlicensed and off-label prescribing of drugs in general practice. Arch Dis Child 2000;83:498–501.PubMedCrossRef McIntyre J, Conroy S, Avery A, Corus H, Choonara I. Unlicensed and off-label prescribing of drugs in general practice. Arch Dis Child 2000;83:498–501.PubMedCrossRef
10.
go back to reference Ekins-Daukes S, Helms PJ, Simpson CR, Taylor MW, McLay JS. Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol 2004;60(5):349–53.PubMedCrossRef Ekins-Daukes S, Helms PJ, Simpson CR, Taylor MW, McLay JS. Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol 2004;60(5):349–53.PubMedCrossRef
11.
go back to reference Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M, The Italian Paediatric Off-label Collaborative Group. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Pediatr 2002;91:339–47.CrossRef Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M, The Italian Paediatric Off-label Collaborative Group. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Pediatr 2002;91:339–47.CrossRef
12.
go back to reference Cuzzolin L, Zaccaron A, Fanos V, et al. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 2003;17(1):125–31.PubMedCrossRef Cuzzolin L, Zaccaron A, Fanos V, et al. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 2003;17(1):125–31.PubMedCrossRef
13.
go back to reference Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonatal 1999;80:F142–5.CrossRef Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonatal 1999;80:F142–5.CrossRef
14.
go back to reference US Food and Drug Administration. Class labeling for intranasal and orally inhaled corticosteroid containing drug products regarding the potential for growth suppression in children. Division of Pulmonary Drug Product. Rockville, MD: US Food and Drug Administration; November 9,1998. Talk Paper. Available at://www.fda.gov/cder/news/cs_label.htm. US Food and Drug Administration. Class labeling for intranasal and orally inhaled corticosteroid containing drug products regarding the potential for growth suppression in children. Division of Pulmonary Drug Product. Rockville, MD: US Food and Drug Administration; November 9,1998. Talk Paper. Available at://www.fda.gov/cder/news/cs_label.htm.
15.
go back to reference ICH Topic E11: Clinical investigation of medicinal products in the paediatric population. European Agency for the Evaluation of Medicinal products, 2001. ICH Topic E11: Clinical investigation of medicinal products in the paediatric population. European Agency for the Evaluation of Medicinal products, 2001.
16.
go back to reference Regulations requiring manufactures to assess the safety and effectiveness of new drugs and biological products in paediatric patients: final rule. Federal register 1998:66631–73. Regulations requiring manufactures to assess the safety and effectiveness of new drugs and biological products in paediatric patients: final rule. Federal register 1998:66631–73.
17.
go back to reference 10th Congress of the United States of America. Best pharmaceuticals for children Act, S.1789 109. 10th Congress of the United States of America. Best pharmaceuticals for children Act, S.1789 109.
18.
go back to reference European Agency for the evaluation of Medicinal Products. Note for guidance on clinical investigation of medical products in children. London: European Agency for the Evaluation of Medicinal products, 1997. European Agency for the evaluation of Medicinal Products. Note for guidance on clinical investigation of medical products in children. London: European Agency for the Evaluation of Medicinal products, 1997.
19.
go back to reference CINECA—Society interuniversity. Progetto ARNO–Paediatrics, Report 2004. Bologna, Italy: Centauro s.r.l.;2005. ISBN 88-85980-46-5. CINECA—Society interuniversity. Progetto ARNO–Paediatrics, Report 2004. Bologna, Italy: Centauro s.r.l.;2005. ISBN 88-85980-46-5.
20.
go back to reference Official Gazette no. 227 29th of September 2005. AIFA: The independent research of drugs financed by AIFA. Official Gazette no. 227 29th of September 2005. AIFA: The independent research of drugs financed by AIFA.
21.
go back to reference Improving children’s medicines: EU reaches final agreement. IP/06/715; June 01 2006. Improving children’s medicines: EU reaches final agreement. IP/06/715; June 01 2006.
Metadata
Title
Unlicensed and off-label use of medicines at a neonatology clinic in Italy
Authors
Maria Dell’Aera
Anna Rita Gasbarro
Margherita Padovano
Nicola Laforgia
Donatella Capodiferro
Biagio Solarino
Roberto Quaranta
Alessandro S. Dell’Erba
Publication date
01-08-2007
Publisher
Kluwer Academic Publishers
Published in
International Journal of Clinical Pharmacy / Issue 4/2007
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-006-9081-z

Other articles of this Issue 4/2007

International Journal of Clinical Pharmacy 4/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.